Lymph node-targeted immune-activation mediated by imiquimod-loaded mesoporous polydopamine based-nanocarriers

Wang, Lu; He, Ye; He, Tingting; Liu, Genhua; Lin, Chongwen; Li, Ké; Lu, Lu; Cai, Kaiyong

doi:10.1016/j.biomaterials.2020.120208

Cited by 81 publications

(60 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And TLR7/8 agonists such as R848 and R837 are synthetic imidazoquinoline-like molecules that function as immune modulators and possess anti-viral and anti-tumor activity 57 . In the study by Wang and coworkers, R837 loaded mesoporous polydopamine nanoparticles (MPDA NPs) was prepared for combinational therapy (Figure 4 A) 58 . The synthesized NPs could encapsulate R837 with high efficiency owing to its porous structure.…”

Section: Nano-based Ptt Combined With Immune Adjuvant For Tumor Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view

et al. 2021

View full text Add to dashboard Cite

Cancer has been a great threat to humans for decades. Due to the limitations of monotherapy, combinational therapies such as photothermal therapy (PTT) and immunotherapy have gained increasing attention with expectation to overcome the shortfalls of each other and obtain satisfactory therapeutic outcomes. PTT can inhibit primary tumors by thermal ablation but usually fails to achieve complete eradication and cannot prevent metastasis and recurrence. Meanwhile, the efficacy of immunotherapy is usually attenuated by the weak immunogenicity of tumor and the immunosuppressive tumor microenvironment (ITM). Therefore, many recent studies have attempted to synergize PTT with immunotherapy in order to enhance the therapeutic efficacy. In this review, we aim to summarize the cutting-edge strategies in combining nano-based PTT with immunotherapy for cancer treatment. Herein, the combination strategies were mainly classified into four categories, including 1) nano-based PTT combined with antigens to induce host immune responses; 2) nano-based PTT in combination with immune adjuvants acting as in situ vaccines; 3) nano-based PTT synergized with immune checkpoint blockade or other regulators to relieve the ITM; 4) nano-based PTT combined with CAR-T therapy or cytokine therapy for tumor treatment. The characteristics of various photothermal agents and nanoplatforms as well as the immunological mechanisms for the synergism were also introduced in detail. Finally, we discussed the existing challenges and future prospects in combined PTT and immunotherapy.

show abstract

Section: Nano-based Ptt Combined With Immune Adjuvant For Tumor Treatmentmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Toll-like receptor (TLR) agonists have been reported to induce DC maturation [134], but as low molecular weight substances, most of them appear to be systematically distributed after a local injection, thus eliminating systemic proinflammatory cascading and severe immune-related toxicity. To address this issue, Wang et al designed a drug delivery system based on mesoporous polydopamine nanoparticles and used the TLR7 agonist imiquimod (R837) as a model immunomodulator to activate immune responses of the lymph nodes [135]. Lymph nodes are important tissues of the immune system [136].…”

Section: Nanoparticle-based Strategies For Melanoma Immunotherapymentioning

confidence: 99%

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics

Song

Liu

Chen

et al. 2021

IJMS

View full text Add to dashboard Cite

Melanoma, as a tumor cell derived from melanocyte transformation, has the characteristics of malignant proliferation, high metastasis, rapid recurrence, and a low survival rate. Traditional therapy has many shortcomings, including drug side effects and poor patient compliance, and so on. Therefore, the development of an effective treatment is necessary. Currently, nanotechnologies are a promising oncology treatment strategy because of their ability to effectively deliver drugs and other bioactive molecules to targeted tissues with low toxicity, thereby improving the clinical efficacy of cancer therapy. In this review, the application of nanotechnology in the treatment of melanoma is reviewed and discussed. First, the pathogenesis and molecular targets of melanoma are elucidated, and the current clinical treatment strategies and deficiencies of melanoma are then introduced. Following this, we discuss the main features of developing efficient nanosystems and introduce the latest reports in the literature on nanoparticles for the treatment of melanoma. Subsequently, we review and discuss the application of nanoparticles in chemotherapeutic agents, immunotherapy, mRNA vaccines, and photothermal therapy, as well as the potential of nanotechnology in the early diagnosis of melanoma.

show abstract

“…Recently, Lu et al. [ 97 ] fabricated a composite nanoparticle by loading TLR 7 agonists into MPDA nanocarriers. To ensure that the TLR agonists moved precisely to the lymphatic tissues, the surface of the composite nanoparticles were modified with polyvinyl pyrrolidone.…”

Section: Polydopamine‐based Multifunctional Platforms For Synergisticmentioning

confidence: 99%

Mussel‐Inspired Polydopamine: The Bridge for Targeting Drug Delivery System and Synergistic Cancer Treatment

Wang

Tang

Zhang

et al. 2020

Macromolecular Bioscience

View full text Add to dashboard Cite

PDA has been applied in the biomedical field that for drug delivery, bioimaging, and tissue engineering biosensing applications. [10-12] Because of its specific structure, PDA is capable of loading antitumor drugs (such as doxorubicin (DOX)) via π-π stacking or hydrogen bonding interactions, with loading rates as high as 91%. Surprisingly, in addition to its strong ability to adsorb drugs, PDA is effective in releasing drugs by internal stimulation (hydrogen peroxide) or from an external stimulus (nearinfrared (NIR) irradiation), reducing the toxic effects of chemotherapeutic drugs. [13-15] Moreover, by exhibiting 40% light-to-heat conversion efficiency, PDA can act as a photothermal agent, able to produce sufficient heat to ablate cancer cells when irradiated with 808 nm NIR light. Compared with other photothermal materials, including carbon or copper-based nanomaterials and gold nanoparticles, the photothermal conversion effect of PDA is greater with better biocompatibility. [16-20] It has been reported that monotherapy has multiple limitations due to its heterogeneity and the drug resistance of tumors, with synergistic therapies that are more effective for cancer treatment. [21] Because of the large number of catechol and amine groups, PDA displays superior adhesion, endowing PDA films with the ability to adhere to a variety of material surfaces, such as gold nanoparticles, iron oxide, silica, and polylactic-co-glycolic acid (PLGA). Thus, PDA has been utilized to functionalize almost every form of nanomaterial by dopamine polymerization. More importantly, a layer of PDA provides nanomaterials with highly desirable properties, including the ability to be loaded with drugs allowing their controlled-release, excellent photothermal conversion efficiency and biocompatibility, and so facilitating the creation of multifunctional drug delivery systems for combined treatment by combining photothermal therapy (PTT) or chemotherapy with other therapies. [22-25] Additionally, the catechol and amino groups on PDA provide a bridge for subsequent modification. For example, PDA can act as a link to introduce tumor-targeting ligands using its amine and thiol groups via a Michael addition or Schiff reaction, allowing nanoparticles to become enriched at the tumor site. [26-28] Using these properties of PDA, researchers have developed diverse forms of PDA-based multifunctional platforms for synergistic cancer therapies. Wang et al. [29] reviewed Polydopamine (PDA), a mussel-inspired molecule, has been recognized as attractive in cancer therapy due to a number of inherent advantages, such as good biocompatibility, outstanding drug-loading capacity, degradability, superior photothermal conversion efficiency, and low tissue toxicity. Furthermore, due to its strong adhesive property, PDA is able to functionalize various nanomaterials, facilitating the construction of a PDA-based multifunctional platform for targeted or synergistic therapy. Herein, recent PDA research, including targeted drug delivery, single-mode therapy, and diverse...

show abstract

Lymph node-targeted immune-activation mediated by imiquimod-loaded mesoporous polydopamine based-nanocarriers

Cited by 81 publications

References 52 publications

Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view

Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics

Mussel‐Inspired Polydopamine: The Bridge for Targeting Drug Delivery System and Synergistic Cancer Treatment

Contact Info

Product

Resources

About